Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 213

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 213
---
     |             | 72 |     |              |  90 |
| Employees and payroll related liabilities |     |              |  61 |     |             |  2 |     |              |  14 |
| Other                                     |     |              |   2 |     |             | 13 |     |              |   9 |
| Total                                     |     |              | 216 |     |             | 87 |     |              | 113 |

NOTE 8 – SHAREHOLDERS’ EQUITY

:

Predecessor

The Ordinary
Shares confer upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in the
distribution of dividends, if any, declared by the Company from legally available funds for the payment thereof, and rights to receive
a distribution of assets upon liquidation.

| During April, May, August and December 2023, the Company signed an                                                                     
 investment agreement with certain investors for gross proceeds of $1,594, according to which the Company received net amount of $1,594 
 and issued 16,244 Ordinary shares NIS 0.1 par value.                                                                                   |

Successor:

On July 23, 2024, the Company issued to the former
Predecessor shareholders an aggregate of 23,171,642 restricted shares of the Company’s common stock, representing 40% of the outstanding
shares of the Company immediately following closing (see note 3).

<div align='center'>F-25</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 8 – SHAREHOLDERS’ EQUITY (Cont.)

Predecessor

On August 10, 2023, the Predecessor adopted the
2023 Share Award Plan to directors, employees and service providers to purchase an aggregate of 23,000 shares of Ordinary shares exercisable
through the tenth anniversary (10th) of date of the issuance.

On November 15, 2023, the Predecessor granted
5,657 options to purchase Company’s 5,657 Ordinary Shares to Company’s Chief Technology Officer. 1,415 options vested on
date of grant, 1,414 options will vest on April 10, 2024, 1,414 options will vest on October 10, 2024, and 1,414 options on April